Flow Pharma's Wholly Owned Foreign Entity (WOFE) JV in China, Hefei Sageland Biotechnology Limited (HSB), recently graduated from the BGI Acceleration Program. During the Program, HSB achieved a strategic cooperation agreement with BGI group relating to Flow Pharma's clinical trial operations in China
NEWARK, CA / ACCESSWIRE / October 23, 2018 / Flow Pharma, Inc. a San Francisco Bay Area based biotechnology company with its FlowVax peptide vaccine platform technology, recently expanded its partnerships in China by working with Miracle Light Incubator. This partnership will help Flow Pharma conduct clinical trials for its FlowVax cancer therapeutic vaccine platform in China.
Hefei Sageland Biotechnology Limited (''HSB''), Flow Pharma's Wholly Owned Foreign Entity (WOFE) JV in China, recently graduated from the BGI Acceleration Program, a star program operated by Miracle Light Incubator. It is a 6-month program, and aims to provide necessary resources for healthcare start-ups to grow in China. Through the program, HSB also achieved economical access to high-quality laboratory services, supporting its clinical trials to evaluate the FlowVax Platform. "We believe such cooperation would benefit both sides, and leverage the impact of advanced biotechnology. And Miracle Light as an equity partner would continue to consolidate such alliance and develop more potential cooperation opportunities.'' said Wyman Zhao, Vice President of Miracle Light Incubator.
BGI Group provides a wide range of next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research institutions and other public and private partners. BGI is headquartered in Shenzhen, China, with branches and medical laboratories in major cities including Beijing, Tianjin, Wuhan, Shanghai and Guangzhou.
''We welcome BGI Miracle Light Incubator as an equity partner, joining our founding partner Button Capital, in HSB. BGI Group is providing critical support to our clinical operations in China and we are delighted that BGI's Miracle Light Incubator has helped us reach agreements with BGI Group enabling us to access these services at a more favorable economic level. Flow Pharma will remain the majority shareholder of the JV,'' said Lu Wang, Ph.D., General Manager of Hefei Sageland Biotechnology Limited.
''We need access to first-class genetic sequencing, immunochemistry, and other precision analytical laboratory services to support our clinical trial operations in China. BGI Group is an outstanding partner to provide these critical resources as we being to screen and treat cancer patients in China,'' said C.V. Herst, Ph.D., Flow Pharma Chief Science Officer.
''China is a very interesting place for us to conduct cancer clinical trials because patients requiring specialty care go to local centers of excellence, simplifying recruitment. This allows us to rapidly conduct clinical studies at at tier-one facilities while working with world-class principal investigators.
We have carefully evaluated BGI Group's capabilities and are very impressed with portfolio of advanced gene sequencing and immunochemistry services they are bringing to support our clinical trials in China. These clinical laboratory services are a major expense driver associated with clinical trials of this kind, and HSB's partnership with BGI Miracle Light Incubator ands BGI Group will significantly decrease our capital requirements for conducting clinical trials in China,'' said Flow Pharma CEO Reid Rubsamen, M.D.
Flow Pharma, Inc. is a San Francisco Bay Area based, pre-clinical stage biotechnology company using artificial intelligence to guide selection of neoantigen peptide targets on cancer cells or virus-infected cells for attack by the patient's own, native immune system. These peptides can then be loaded into the FlowVax platform for administration by injection.
Flow Pharma, Inc. is preparing to test therapeutic cancer vaccines targeting neoantigens found in various cancers. Neoantigens are small peptide markers expressed on cancer cells as a result of a cancer-causing viral infection or mutation of the DNA in normal cells that cause transformation into cancer cells.
About Miracle Light Life Science Incubator and BGI Group
Initiated by BGI Group, in partnership with co-investors Green Pine Capital Partners, Cowin Capital and Mr. Luming Zhou, initiator of China Radical Innovation 100, Miracle Light Life Science Incubator serves global entrepreneurs that solve challenges in the fields of pharmaceuticals, medical treatment, healthcare, food, agriculture and ecology based on life science research and respective Internet applications.
Built upon the expertise and resources of BGI Group, the world's largest gene sequencing company and bioinformatics center, Miracle Light Life Sciences Incubator provides enterprise incubation services including access to laboratory space, specialized equipment and access to capital for companies that could benefit from the BGI Group's portfolio of resources. Miracle Light Life Science Incubator aims to develop entrepreneurial ecosystems for new life science companies to help bring forward the next wave of health care technologies.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of Flow Pharma, Inc. (''the Company''), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words ''believes,''''expects,''''intends,''''plans,''''anticipates,'' or ''may,'' and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc.
Media Contact
Investor Relations
Flow Pharma, Inc.
39655 Eureka Drive
Newark, California 94560
760-564-7400
[email protected]
SOURCE: Flow Pharma, Inc.